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Abstract
Background: Inflammatory mediators in both the peripheral circulation and central nervous system (CNS) are
dysregulated in major depressive disorder (MDD). Nevertheless, relatively little is known about the role of the
T-helper (Th)-2 effector cytokines interleukin (IL)-5 and IL-13 in MDD.
Methods: We examined the serum levels of these cytokines and a Th-1 comparison cytokine, interferon (IFN)-g,i n
116 individuals (MDD, n = 58; controls, n = 58).
Results: In our basic multivariate model controlling for the effects of potential confounders on the associations
between MDD and the examined cytokines, each 1-unit increase in the serum IL-5 level increased the likelihood of
belonging to the MDD group by 76% (OR 1.76, 95% CI 1.03-2.99, p = 0.04; model covariates: age, gender, marital
status, daily smoking and alcohol use). The likelihood further increased in models additionally controlling for the
effects of the use of antidepressants and NSAIDS, and a diagnosis of asthma. No such associations were detected
with regard to IL-13 (OR 1.08, 95% CI 0.96-1.22, p = 0.22) or IFN-g (OR 1.02, 95% CI 0.99-1.05, p = 0.23).
Conclusions: Elevated levels of IL-5, which uses the neural plasticity-related RAS GTPase-extracellular signal-
regulated kinase (Ras-ERK) pathway to mediate its actions in the central nervous system (CNS), could be one of the
factors underlying the depression-related changes in CNS plasticity.
1. Background
According to the monocyte-T-lymphocyte hypothesis of
major depression, the pathophysiology of major depres-
sive disorder (MDD) anticipates immune system activa-
tion [1]. Cytokines are immune system signaling
molecules that affect the synthesis, release, and cell reup-
take of monoamines [2]. Both their absence and over-
expression affects central nervous system functions such
as synaptic plasticity, neurogenesis, and neuromodulation
in varying ways, including activity within basal ganglia
and the frontal cortex [3-6]. They also modulate the
activity of the hypothalamus-pituitary axis (HPA), which
is a central factor in the pathogenesis of MDD [7].
Several studies have indicated MDD as an inflamma-
tory state with elevated levels of proinflammatory cyto-
kines [e.g. Interleukin (IL)-6 and -12 and interferon
(IFN)-g] [8]. Cytokines such as IL-1 and tumor necrosis
factor (TNF)-a are also dysregulated, and they have been
suggested to serve as neuroplasticity-modulating factors
in MDD neuropathology [9]. Moreover, much emphasis
has been placed on the imbalance between T-helper (Th)
cell cytokines Th1 and Th2 in the pathogenesis of MDD
[10]. While MDD is linked to disturbance in the homeos-
tasis of immune systems [7,11], it also increases the likeli-
hood of several somatic conditions such as cardiovascular
diseases, diabetes, and cancer [12], as well as asthma and
other allergic conditions [13]. In particular, asthmatic
adolescents have a significantly increased risk of the early
development of psychiatric disorders, while MDD
patients with comorbid asthma suffer from greater
impairments in asthma symptoms [14].
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duction of cytokines [15]. Th cells are mainly divided
into two types according to their polarization. Th1 cells
regulate cell-mediated immune responses and are charac-
terized by IL-2 and IFN-g production [16]. IFN-g has var-
ious immunoregulatory actions. Its biological responses
are closely integrated with the other cytokine mechan-
isms, with signaling pathways especially cross-talking
with IFN-a [17]. IFN-g is one of most studied cytokines
in MDD [18]. Th2 cells regulate humoral immunity via
B-cell actions by producing IL-4, IL-5, and IL-13 [19].
Furthermore, other T-cells such as Th17 and regulatory
T-cells have emerged as important factors controlling
immune responses and inflammation [20].
Cytokines IL-5 and IL-13 play important roles in the
pathophysiology of various autoimmune diseases such as
asthma [21] and Graves’ disease [22]. IL-4 mainly func-
tions by activating Th2 cells, while IL-5 and IL-13 work
as effector cytokines of activated Th2 cells, i.e. they are
secreted by Th cells after the cells are activated [23]. Ele-
vated levels of IL-13 and lower levels of IFN-g have been
associated with MDD [24]. Interestingly, possible routes
b e t w e e nI L - 5a n dM D Dh a v ea l s ob e e ns t a t e d .T h e r ei sa
genetic risk for MDD through the colony stimulating fac-
tor 2 receptor b (CSF2RB) haplotype, which encodes a
protein in high affinity receptors binding IL-5 [25].
Furthermore, a gene set analysis of post-mortem brain
tissue has suggested the upregulation of IL-5 levels in
MDD [26]. However, to the best of our knowledge, there
have been very few studies examining IL-5 and IL-13 in
relation to MDD.
The goal of this study was to examine the roles of the
Th2 effector cytokines IL-5 and IL-13 and an established
comparison Th1 cytokine, IFN-g,i nM D D .W h i l eI L - 4
has been intensively studied with regard to MDD,
increasing evidence has accumulated of the roles of other
Th2 cytokines in contributing to neuromodulatory altera-
tions similar to those observed in MDD (e.g., impaired
neuroplasticity). Thus, individuals with MDD would be
likely to show elevations in the secretion of these cyto-
kines. IFN-g was chosen because of its central relation-
ship with MDD, and due to its comparative role to the
Th2 cytokines as a Th1 cytokine.
2. Methods
The study was conducted as part of the Kuopio Depres-
sion (KUDEP) four-phase general population study invol-
ving adults aged 25-64 years in the province of Kuopio in
Eastern Finland. A random sample of 3004 participants
was selected in 1998 from the National Population Regis-
ter and was followed up in 1999 and 2001. The baseline
sample included 2050 participants, the first follow-up sam-
ple (1999) 1722 participants, and the second follow-up
sample (2001) 1593 participants. The second follow-up
questionnaire was only sent to those subjects who
responded in either of the preceding surveys. Question-
naires were re-sent to the non-respondents one month
later after each follow-up. Participants responded to ques-
tions concerning their age, gender, marital status (married
or living with a partner vs. living alone), asthma diagnosis
by a physician (yes vs. no), daily smoking (yes vs. no), alco-
hol use (≥ 2 times per week vs. less), and the use of antide-
pressant medications (yes vs. no).
In 2005, a sub-sample of 427 participants from the pre-
vious study phases reporting either high or low levels of
adverse mental symptoms were asked to take part in a
clinical evaluation and laboratory testing [27,28] as a
fourth study phase. For the present study, we selected
those participants whose Beck Depression Inventory (BDI)
[29] scores indicated depressive symptoms (BDI scores ≥
10; depressed) or a euthymic state (BDI scores ≤ 9; con-
trols) consistently at all three earlier data collection points.
The mean BDI scores (standard deviation, SD) for the
depressed (n = 58) were 18.1 (9.1) in 1998, 21.5 (9.9) in
1999, and 20.9 (11.1) in 2001. The corresponding means
(SD) for the controls (n = 58) were 2.6 (2.2) in 1998, 2.9
(2.6) in 1999, and 2.1 (1.9) in 2001.
Psychiatric interviews were conducted for all partici-
pants, including the controls, by a trained, experienced
research nurse using the Structured Clinical Interview for
DSM-IV (SCID-I and SCID-II) [30-32]. Additionally, the
29-item Hamilton Depression Rating Scale (HAM-D-29)
[33] was used for the assessment of depression severity.
The HAM-D-29 includes the 21-item Hamilton Depres-
sion Rating Scale (HAM-D-21) with a supplementary 8-
item subscale (Atypical Depression Supplement, ADS) for
measuring atypical features of depression. The ADS
includes questions regarding weight gain, increased appe-
tite/eating, carbohydrate craving, hypersomnia, leaden
paralysis, and social withdrawal. Subjects with bipolar dis-
orders were excluded and the primary diagnosis for all the
rest of the depressed participants was MDD. Data con-
cerning the participants’ somatic medications were
acquired from the nationwide Social Insurance Institute.
Approval for the study was obtained from the Ethics Com-
mittee of Kuopio University Hospital and the University of
Eastern Finland. The study protocol was in accordance
with the Declaration of Helsinki. All participants provided
written informed consent before entering the study.
After the clinical interviews, the participants were given
a referral to the laboratory, and were then instructed to
visit the laboratory at the latest during the following
week. The body mass index (kg/m
2) was calculated from
height and body weight measured in light clothing with-
out shoes. The venous blood serum samples for the cyto-
kine analyses were stored at -80°C until run. IL-5 (pg/
mL), IL-13 (pg/mL) and IFN-g (pg/mL) levels were ana-
lyzed by multiplexing with Bio-Plex Human Cytokine
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Luminex xMAP technology (Bio-Rad Laboratories Inc.,
CA, US). The Luminex method and the standard
enzyme-linked immunosorbent assay (ELISA) are highly
correlated [34-36]. Before analyses, the samples were cen-
trifuged for 15 min at 3000 rpm, and diluted 1:2 in a
sample matrix. The samples were assayed singly, and the
assay conditions were standardized and pre-optimized to
ensure optimal reproducibility of the assays. The kit
instructions and instrument manuals were followed
accordingly. The intra-assay and interassay variation for
the kit analyses were 4.6-13.8% and 3.7-17.2%, respec-
tively. The results were calculated with BioPlex Manager
Software version 4.3 with five-parameter logistic equa-
tions [37]. High sensitivity range standard settings were
utilized. The values between zero (blank sample) and the
lowest standard (IL-5: 0.52 pg/ml; IL-13: 0.71 pg/ml;
IFN-g: 0.30 pg/ml) were extrapolated from the standard
curve by the software. In statistical analyses, the non-
detectable samples (ND) were marked as the mean value
between zero and the lowest extrapolated value of each
cytokine [38]. There were 17 NDs for IL-5, 30 for IL-13,
and 52 for IFN-g.
The data were analyzed using SPSS version 17.0 statis-
tical software (SPSS Inc., Chicago, IL). Differences
between the MDD and control groups were assessed
using the chi-squared test for categorical variables, and
the Student’s t-test and the Mann-Whitney U-test for
continuous variables. Parametric tests were used with
normally distributed and non-parametric tests with non-
normally distributed variables. The differences between
the MDD and control groups in the examined cytokines
were further examined with logistic regression modeling.
The modeling was performed in two steps. First, we
formed a basic model consisting of general parameters
either showing differences between the groups or known
to affect the levels of IL-5, IL-13 or IFN-g (Model 1: age,
gender, marital status, alcohol use [39], and daily smok-
ing [40]). Secondly, for more comprehensive evaluation
of the effects of potential confounders, we formed models
that included the variables in Model 1 together with
further adjustments for one of the following covariates:
the use of antidepressants (Model 2), the use of NSAIDs
(Model 3), and a diagnosis of asthma (Model 4). The
cytokines were inserted into the models as continuous
variables. The odds ratios (OR) show the likelihood for
each 1-point increase in the serum levels of these cyto-
kines, i.e. OR show the odds for a covariate belonging to
the MDD group in relation to the control group.
3. Results
The characteristics of the study population are presented
in Table 1. The individuals in the MDD group more often
lived alone, smoked, and used antidepressant medication.
They also showed higher scores on all the depression
scales used in the present study, i.e. HAM-D-21, HAM-D-
29, ADS, and BDI. The levels of IL-5, IL-13 and IFN-g did
not significantly differ between the groups in the crude
analysis. Moreover, scatterplots were formed to visualize
the relationships between IL-5 (Figure 1), IL-13 (Figure 2)
and IFN-g ( F i g u r e3 )a n dt h eB D Is c o r e sf r o mt h e2 0 0 5
questionnaire.
In the multivariate models (Table 2) controlling for the
effects of potential confounders on the associations
between depression and the examined cytokines, each 1-
unit increase in the serum IL-5 levels increased the likeli-
hood of belonging to the MDD group by 76% (OR 1.76,
95% CI 1.03-2.99, p = 0.038) in Model 1 adjusted for age,
gender, marital status, daily smoking, and alcohol use.
The observations remained essentially similar in the
other models further adjusted for the use of antidepres-
sants (Model 2: OR 2.06, 95% CI 1.16-3.63, p = 0.013),
the use of NSAIDS (Model 3: OR 1.89, 95% CI 1.10-3.27,
p = 0.022) and a diagnosis of asthma (Model 4: OR 1.83,
95% CI 1.07-3.14, p = 0.028). No such associations were
observed for IL-13 or IFN-g (Table 2).
4. Discussion
4.1 Main findings
The elevation of serum levels of IL-5 was associated with
an increased likelihood for belonging to the group with
MDD. No such associations were detected with regard to
IL-13 or IFN-g.
4.2 Previous literature
Previous data on the connections between IL-5 and
MDD are scarce. However, a recent post-mortem gene
set analysis suggested an up-regulation of IL-5 levels in
the frontal cortices of individuals with MDD [26]. Our
findings were consistent with this observation, demon-
strating similar elevations in circulating levels of IL-5.
This is also in line with studies showing elevated levels of
other Th2 cytokines, such as IL-4 and IL-13 [41]. On the
other hand, a study by Simon et al. (2008) [42] revealed
no difference in IL-5 levels between the MDD group and
controls. These findings, however, were not adjusted for
potential confounders such as smoking, which appears to
lower the levels of serum IL-5 [40]. Thus, the lack of
adjustment for smoking in the study by Simon et al., as
well as in our study with respect to our initial cross-
sectional association (Table 1), may underlie our observa-
tion of only borderline significance for elevated IL-5
levels in MDD.
Elevated levels of IL-13, IFN-g, and the Th1/Th2 ratio
have been detected in MDD [19]. In our study, the indivi-
duals with MDD had higher overall levels of both IL-13
and IFN-g, but this difference did not reach statistical sig-
nificance. However, the small study population of the
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tistical errors, leading to the lack of detection of an actual
difference in the cytokine levels between the study
groups. Moreover, the studies of Pavón et al. (2006) [24]
and Hernández et al. (2008) [41] represented patient
populations and not a random cohort from a general
population, and were thus more severely depressed. The
mean HAM-D-21 score for the depressed group reported
by Hernández et al. was 20.3, and the HAM-D-17 score
in the study of Pavón et al. was 24.2, whereas in our
MDD group the mean HAM-D-21 score was 12.0. Thus,
cytokine differences are likely to be less pronounced in a
population-based sample consisting of individuals with a
depression score lower than those observed in patient
samples.
In this study there was no significant relationship
between MDD and asthma. Although there is very little
Table 1 The characteristics of the study participants
MDD Controls
n = 58 n = 58 Statistics* p-value
Age 53.40 ± 1.22 53.21 ± 1.20 t = -0.011 0.912
a
Female, n (%) 40 (69.0) 40 (69.0) c
2 = 0.00 1.000
b
Married or living with a partner, n (%) 48 (82.5) 55 (94.8) c
2 = 5.25 0.039
b
Daily smoking, n (%) 18 (31.0) 4 (6.9) c
2 = 10.99 0.001
b
Alcohol use, ≥ 2 times per week (%) 9 (15.5) 10 (17.2) c
2 = 0.06 0.802
b
Asthma, n (%) 3 (5.2) 5 (8.6) c
2 = 0.537 0.464
b
BMI (kg/m
2) 27.24 ± 0.86 27.13 ± 0.65 Z = -0.04 0.967
c
HAM-D-21 12.00 ± 0.73 2.98 ± 0.36 Z = -8.00 < 0.001
c
ADS 2.84 ± 0.43 0.59 ± 0.13 Z = -4.04 < 0.001
c
HAM-D-29 14.84 ± 0.99 3.57 ± 0.41 Z = -7.86 < 0.001
c
BDI 17.68 ± 0.97 3.55 ± 0.41 Z = -8.77 < 0.001
c
Use of NSAIDs, n (%) 7 (12.1) 1 (1.7) – 0.061
d
Use of oral corticosteroids, n (%) 5 (8.6) 3 (5.2) – 0.717
d
Use of antidepressants, n (%) 22 (37.9) 4 (6.9) c
2 = 16.06 < 0.001
b
IL-5 (pg/ml) 0.81 ± 0.13 0.54 ± 0.08 Z = -1.87 0.061
c
IL-13 (pg/ml) 7.51 ± 6.05 0.89 ± 0.22 Z = -0.60 0.549
c
IFN-g (pg/ml) 12.03 ± 5.96 3.03 ± 0.91 Z = -0.43 0.664
c
IFN-g/IL-5 ratio 6.97 ± 1.99 24.69 ± 11.16 Z = -0.39 0.697
c
Values are means ± standard errors unless otherwise stated.
a Student’s t-test;
b Chi-squared test;
c Mann-Whitney U-test;
d Fisher’s exact test; * Where applicable
Abbreviations: ADS = atypical depression supplement; BMI = body mass index, BDI = Beck Depression Inventory, HAM-D = Hamilton Depression Rating Scale, IL =
interleukin, MDD = major depressive disorder; NSAID = non-steroidal anti-inflammatory drug
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Figure 1 S c a t t e r p l o to fI L - 5l e v e l si nr e l a t i o nt oB D Is c o r e s
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Figure 2 Scatterplot of IL-13 levels in relation to BDI scores
from the 2005 questionnaire.
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necting asthma and MDD, Th2 cytokines appear to play
a role in the pathophysiology of both of these diseases
[25,26,43], as asthma and other similar inflammatory
diseases have been shown to increase the risk and symp-
toms of MDD [14].
4.3 Possible mechanisms
Peripheral cytokines can cross the blood-brain barrier,
influencing complex brain functions both directly and
indirectly [12,44]. Pavón et al. (2006) [24] hypothesized
that the elevated circulatory cortisol levels associated
with MDD could lead to abnormal patterns of synthesis
and secretion of Th2 cytokines, thus provoking the
depressive symptoms. This may involve several possible
mechanisms.
Relatively little is known about IL-5. Most previous stu-
dies have not detected alterations in the levels IL-5 of
MDD patients [42]. However, IL-5 activates several inter-
esting signaling pathways, with activation of Januse
kinase 2 (JAK) 2 and STAT5 being the most essential.
The JAK-STAT pathways play important roles in cell
proliferation and survival in both the CNS and the per-
iphery through specific and diverse effects on cell
responses to hormones, growth factors and cytokines
[45,46], while its activation can lead to depressive effects
through glucocorticoid signaling [47]. IFN-a and -g have
also been shown to activate JAK family kinases and con-
sequently phosphorylate STATs [48], and further induce
depressive symptoms [49]. In addition to JAK-STAT
pathways, IL-5 uses the Ras GTPase-extracellular signal-
regulated kinase (Ras-ERK) pathway. IL-5 can activate
the Ras-ERK pathway [50], which controls neural stem
cell functions and maintains specific brain structures
[51]. Hyperactivity of Ras-ERK pathways has been
observed to cause deficits in synaptic plasticity and hip-
pocampus-related learning in mice [52]. Such mechan-
i s m sm a yp l a yar o l ei nd e p r e s s i o n .T h u s ,t h ee l e v a t e d
levels of IL-5 could be one of the factors inducing a
depression-related decrease in central nervous system
plasticity.
4.4 Strengths and limitations
One of our strengths in this study was the comprehensive
evaluation of depressive symptomatology. In evaluating
and diagnosing MDD, we used the Structured Clinical
Interview for DSM-IV, as well as self-reported and inter-
viewer-rated depression scales. Moreover, several factors
such as antidepressant use [53], lifestyle factors [39,40],
and various somatic medications and diseases such as
asthma [14] affect the levels of cytokines expressed in cir-
culation. Nevertheless, we were able to examine the
effects of these potential confounders on our findings,
even though the somatic conditions were self-reported.
The depressed subjects in the present study suffered
homogeneously from MDD, while those with bipolar dis-
order were excluded. The study population also solely
consisted of individuals of Finnish descent, thus minimiz-
ing the potential confounding effect of genetic variation
on our findings. The main limitation of our study was
the small sample size, increasing the risk of type II statis-
tical errors, which might have resulted in the lack of
detection of actual significant differences between the
groups. The high interassay variation in analysis could
have also interfered with the ability to detect differences
in cytokine levels. Secondly, due to the cross-sectional
study design, we were unable to assess causality or con-
firm previous suggestions of possible biological routes. A
fairly large number of conditions affect serum IL-5 levels,
and despite statistical adjustment for known confoun-
ders, there remains the potential for residual confound-
ing. Thirdly, we did not have data on some somatic
conditions related to the secretion of some of the mea-
sured cytokines (e.g. allergic rhinitis, atopic dermatitis),
which may have affected our findings. IL-13 may be asso-
ciated with allergic rhinitis when the individuals are pro-
voked with an allergen [54]. However, some data are
available suggesting that the levels of IL-5 and IFN-g are
unaffected even in the presence of an allergen [54].
Furthermore, to the best of our knowledge, these condi-
tions are not clearly associated with MDD; thus, it is unli-
kely that these individuals would specifically concentrate
in the MDD group. Lastly, a general guideline indicates
that the number of non-detectable samples can be con-
sidered small when they comprise less than 30% of the
total sample size [38]. In this study, the proportions of
non-detectable samples forI L - 5a n dI L - 1 3w e r eb e l o w
the 30% limit, but IFN-g exceeded this limit. However,
IFN-gamma (pg/ml)
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Figure 3 Scatterplot of IFN-g levels in relation to BDI scores
from the 2005 questionnaire.
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Age Gender Marital status Daily smoking Alcohol use Cytokine* Additional covariate (antidepressant/
NSAIDs/asthma)
Model OR P CI95% OR p CI95% OR p CI95% OR p CI95% OR p CI95% OR p CI95% OR p CI95%
IL-5* 1.
a 1.03 0.24 0.98-1.08 1.37 0.49 0.56-3.35 4.05 0.67 0.91-17.96 7.95 0.001 2.34-27.03 1.62 0.40 0.52-5.04 1.76 0.04 1.03-2.99 - - -
2.
b 1.01 0.69 0.96-1.06 1.51 0.41 0.56-4.06 4.23 0.85 0.82-21.76 10.59 0.001 2.87-39.15 2.32 0.18 0.68-7.88 2.06 0.013 1.16-3.64 11.98 0.001 3.25-44.16
3.
c 1.04 0.15 0.99-1.09 1.30 0.58 0.52-3.30 3.99 0.076 0.87-18.39 9.08 0.001 2.60-31.73 1.94 0.29 0.57-6.53 1.89 0.022 1.10-3.27 0.084 0.033 0.01-0.82
4.
d 1.03 0.24 0.98-1.08 1.31 0.56 0.53-3.25 3.80 0.81 0.85-17.01 8.60 0.001 2.46-30.09 1.67 0.38 0.54-5.17 1.83 0.028 1.07-3.14 2.45 0.30 0.45-13.43
IL-13* 1
.a 1.03 0.23 0.98-1.08 1.26 0.61 0.52-3.03 4.50 0.044 1.04-19.50 7.51 0.001 2.22-25.33 1.47 0.50 0.48-4.50 1.08 0.22 0.96-1.22 - - -
2.
b 1.01 0.69 0.96-1.06 1.30 0.59 0.50-3.36 4.49 0.066 0.91-22.24 9.24 0.001 2.54-33.58 2.02 0.26 0.60-6.84 1.06 0.33 0.94-1.20 0.098 0.001 0.027-0.35
3.
c 1.04 0.15 0.99-1.09 1.19 0.71 0.48-2.94 4.35 0.054 0.97-19.47 8.36 0.001 2.41-29.07 1.70 0.39 0.51-5.63 1.09 0.186 0.96-1.24 0.095 0.039 0.10-0.89
4.
d 1.03 0.22 0.98-1.08 1.20 0.69 0.49-2.91 4.24 0.055 0.97-18.54 8.18 0.001 2.35-28.52 1.47 0.50 0.48-4.50 1.10 0.14 0.97-1.24 2.65 0.29 0.44-15.87
IFN-g*1 .
a 1.03 0.21 0.98-1.08 1.32 0.54 0.55-3.19 3.92 0.069 0.90-17.09 7.41 0.001 2.19-25.14 1.61 0.42 0.51-5.05 1.02 0.23 0.99-1.05 - - -
2.
b 1.01 0.66 0.96-1.06 1.31 0.57 0.51-3.40 3.86 0.094 0.80-18.74 8.95 0.001 2.46-32.47 2.15 0.23 0.62-7.41 1.01 0.22 0.99-1.04 0.10 0.001 0.029-0.37
3.
c 1.04 0.15 0.99-1.09 1.22 0.67 0.49-3.02 4.18 0.062 0.93-18.85 8.04 0.001 2.32-27.83 1.74 0.37 0.52-5.80 1.02 0.25 0.99-1.05 0.11 0.053 0.011-1.03
4.
d 1.03 0.21 0.98-1.08 1.28 0.59 0.53-3.11 3.77 0.078 0.86-16.49 7.63 0.001 2.23-26.16 1.61 0.41 0.52-5.05 1.02 0.23 0.99-1.05 1.72 0.52 0.33-8.88
a Covariates for Model 1: gender, age, marital status, daily smoking, and alcohol use
b Covariates for Model 2: gender, age, marital status, daily smoking, alcohol use, and antidepressant use
c Covariates for Model 3: gender, age, marital status, daily smoking, alcohol use, and NSAIDs use
d Covariates for Model 4: gender, age, marital status, daily smoking, alcohol use, and diagnosis of asthma
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8since all the imputed values were close to zero, the effect
of the imputation method on the total variance is likely
to have been very small.
5. Conclusions
We have been able to demonstrate that an increased
likelihood of MDD was associated with elevated levels
of IL-5. Elevated IL-5, which uses the neural plasticity-
related RAS-ERK pathway to mediate its actions in the
CNS, could be one of the factors underlying depression-
related changes in CNS plasticity. Further studies are
needed to more thoroughly understand the exact biolo-
gical mechanisms through which IL-5 is linked to
depression
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